ArticleFrontiers in nutrition2026
Gut microbiota mediates the anti-obesity effects of
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity constitutes a pressing global public health challenge, characterized by intricate associations with metabolic dysregulation and gut microbiota dysbiosis. Methods: This study systematically evaluated the anti-obesity efficacy and underlying mechanisms of Results: GAE intervention significantly ameliorated HFD-induced metabolic disorders, as evidenced by reduced oxidative stress, enhanced glucose tolerance, suppressed visceral adiposity, and attenuated chronic low-grade inflammation. Mechanistically, GAE preserved intestinal barrier integrity through upregulation of tight junction protein expression. Multi-omics integration of 16S rRNA gene sequencing and untargeted metabolomics revealed that GAE substantially rectified gut microbiota dysbiosis and lipid metabolic disturbances, mediated by specific bioactive metabolites-including lysophosphatidylcholine 22:6 and N-oleoyl glycine-and enrichment of beneficial bacterial genera ( Conclusion: Collectively, these findings establish that GAE exerts multi-target anti-obesity effects through modulation of the "microbiota-gut-metabolism" axis, providing compelling preclinical evidence supporting the development of GAE as a functional food ingredient for weight management applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.